
Sunvozertinib
CAS No. 2370013-12-8
Sunvozertinib( —— )
Catalog No. M35766 CAS No. 2370013-12-8
Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor, with inhibitory effects on EGFR, Her2, and mutant epidermal growth factor.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 46 | Get Quote |
![]() ![]() |
5MG | 55 | Get Quote |
![]() ![]() |
10MG | 78 | Get Quote |
![]() ![]() |
25MG | 122 | Get Quote |
![]() ![]() |
50MG | 205 | Get Quote |
![]() ![]() |
100MG | 353 | Get Quote |
![]() ![]() |
500MG | 1314 | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameSunvozertinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionSunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor, with inhibitory effects on EGFR, Her2, and mutant epidermal growth factor.
-
DescriptionSunvozertinib (DZD9008) is a potent ErbBs (EGFR, Her2, especially mutant forms) and BTK inhibitor. Sunvozertinib shows IC50s of 20.4, 20.4, 1.1, 7.5, and 80.4 nM for EGFR exon 20 NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutations, and Her2 Exon20 YVMA, and EGFR WT A431, respectively (patent WO2019149164A1, example 52).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR | BTK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2370013-12-8
-
Formula Weight584.08
-
Molecular FormulaC29H35ClFN7O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (85.60 mM; Ultrasonic (<80°C)
-
SMILESCOc1cc(N2CC[C@H](C2)N(C)C)c(NC(=O)C=C)cc1Nc1nccc(Nc2cc(Cl)c(F)cc2C(C)(C)O)n1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Zhengtao LI, et al. Erbb/btk inhibitors. WO2019149164A1.
molnova catalog



related products
-
EGFR/ErbB2 Inhibitor
EGFR/ErbB2 Inhibitor is a cell-permeable inhibitor of EGFR and c-ErbB2 (IC50s = 20 and 79 nM, respectively)
-
Gefitinib
A potent, selective, orally active EGFR inhibitor with IC50 of 23 nM; inhibits EGF-stimulated proliferation of KB cells with IC50 of 80 nM.
-
Lazertinib
Lazertinib (YH25448, GNS-1480) is a highly potent, mutant-selective, irreversible, brain-penetrant and orally active EGFR tyrosine-kinase inhibitors for both the T790M mutation and activating EGFR mutations.